The UK faces risks of AI power deficit due to reliance on foreign technology, prompting calls for government support to develop domestic computing capabilities and reduce dependency.
Novartis nears $12B acquisition of Avidity Biosciences, a biotech with a platform for delivering RNA therapeutics to muscle tissue.
The UK faces risks of AI power deficit due to reliance on foreign technology, prompting calls for government support to develop domestic computing capabilities and reduce dependency.
Novartis nears $12B acquisition of Avidity Biosciences, a biotech with a platform for delivering RNA therapeutics to muscle tissue.
